REG-Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Genmab reported updated Phase 2 data showing petosemtamab plus pembrolizumab achieved a 28.2-month median overall survival in first-line recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma, roughly 2.5x the historical 10-12 month benchmark. The efficacy-evaluable population (n=43) showed a 63% overall response rate, 19% complete response rate, and 9.0-month median PFS, with responses observed across both HPV-positive and HPV-negative disease and no treatment-related deaths. The Phase 3 LiGeR-HN1 trial in this indication is ongoing with topline data anticipated later this year, and Genmab will host an investor update on October 28.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 2
- Orr pct
- 63
- Median dor
- not reached
- Median pfs months
- 9
- 12 month os rate pct
- 79
- Complete response rate pct
- 19
- Efficacy evaluable patients
- 43
- Historical median os r m hnscc
- 10-12 months
- Median overall survival months
- 28.2
- Responders maintaining response 24mo pct
- 55
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.